Case studies

MedAccess: volume guarantees that bring health products to market

A UK-based social finance company, capitalised with USD 170 million by British International Investment, that uses volume guarantees to persuade manufacturers to supply medical products to low- and middle-income countries at lower prices and in markets they would not otherwise enter. Grant-funded for operations by FCDO, the Gates Foundation, and Wellcome.

Last reviewed
Related chapter
Chapter Four (water case, the guarantee mechanism); Chapter Five, section 7 (guarantees and insurance)
Sectors
Health
Geography
Global; 120-plus countries reported
Vehicles
Public-private catalytic platform (guarantee-based)

The problem

Manufacturers of vaccines, diagnostics, and treatments face uncertain demand in low-income markets. Without a demand signal, they either do not enter, or enter at prices that procurers cannot afford. Procurers (governments, Gavi, the Global Fund, UNICEF) face the mirror problem: they cannot commit to volume without a price, and manufacturers will not commit to price without volume.

How the structure works

MedAccess signs a volume guarantee with a manufacturer. The manufacturer agrees to supply a product at a reduced price; MedAccess guarantees that if purchase volumes fall below an agreed floor, it will pay the shortfall. Procurers then buy at the reduced price. In most cases the volume floor is met and the guarantee is never called. MedAccess charges a fee that covers its costs of structuring and monitoring.

Who provides capital, in what form

British International Investment (the UK's development finance institution) provided USD 170 million of capital, which stands behind the guarantees. FCDO, the Gates Foundation, and Wellcome provide grants (since 2021) for the scoping, negotiation, and execution of agreements. In 2025 the European Investment Bank announced a counter-guarantee of up to EUR 52 million covering up to 30 percent of potential losses on eligible African health guarantees.

Who absorbs risk

MedAccess absorbs the volume risk. If demand falls short, it pays. The manufacturer is protected against the downside of a lower price; the procurer gets the lower price without having to commit to volumes it cannot yet forecast.

What makes it catalytic

This is the book's "guarantee that is almost never called" in practice. The capital sits on MedAccess's balance sheet, still earning, still counted. What moves the market is its availability, not its expenditure. The 2025 accounts show a volume guarantee contract liability of around USD 1.6 million against net exposure of around USD 128 million, which gives a sense of how rarely the guarantees are expected to pay out.

Sequence

Manufacturer and procurer are stuck. MedAccess guarantees the volume floor. Manufacturer commits to price and supply. Procurers buy. Demand materialises. Guarantee expires unused. Lower price persists because the market has been demonstrated.

Reported results (MedAccess, cumulative since 2017 to end 2025, selected agreements)

  • 18 transactions in the portfolio; 6 signed in 2025.
  • USD 872 million in sales enabled; USD 228 million in direct procurer savings.
  • 2.6 million children vaccinated against malaria (RTS,S).
  • 31 million pregnant women accessed a dual HIV/syphilis test across more than 60 countries; USD 13.6 million saved for procurers on that product.
  • 162,000 stillbirths averted; 3.8 million additional children reached with vitamin A; 19,800 people started HIV treatment; 46,200 people with multidrug-resistant TB with improved outcomes.
  • Manufacturers entered 24 new markets in 2025.

Limitations and unresolved questions

The figures cover selected agreements, not the whole programme. They are "additional" figures projected against a counterfactual scenario without MedAccess intervention; the method is MedAccess's own and the accounts say so. People-reached figures are health outcomes attributed to products MedAccess helped bring to market, not outcomes it delivered directly; MedAccess itself says it focuses "on our contribution to change, not on claiming credit for others' success." No guarantee calls or realised losses are reported in the 2025 accounts, which means the model has not yet been tested by a demand shortfall large enough to trigger payment.

Practical lesson

For a foundation board that fears loss more than stagnation, this is the instrument to study. The guarantee lets a cautious institution act catalytically without the capital leaving the balance sheet. The condition is that someone with sector expertise (here, MedAccess) does the structuring; a guarantee badly priced is a subsidy with a better name.

Related book concept

Chapter Five, section 7, the passage on guarantees and insurance as "the first tool a cautious foundation reaches for, and usually the last."

Sources

  1. MedAccess — 2025 Annual Review and Accounts

Educational material, not investment, legal or tax advice. Reported figures and review dates reflect the cited sources and editorial review; they are not live data.

MAD. Entrepreneurs Making A Difference

A capital platform backing growth-stage companies applying new science and engineering to restore the systems humanity depends on.

MAD VenturesLevel 3, 180 George StreetSydney NSW 2000, Australia

hello@mad.vc

The MAD Briefing

Capital, founders, and system change for the next cycle. Direct to your inbox.

Acknowledgement of Country. MAD acknowledges the Traditional Owners of the lands on which we live and work, the Gadigal people of the Eora Nation. We pay our respects to Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander people.

Important Information

Information for eligible Australian wholesale clients and US accredited investors only. The information on this website is general information only and does not constitute financial, tax, legal, investment, or other professional advice. It does not constitute an offer of securities for sale or an invitation to purchase or subscribe for securities. Any investment opportunity referenced is offered privately and only to wholesale clients as defined under sections 761G and 708(8) of the Corporations Act 2001 (Cth), and to eligible US accredited investors under applicable US law, under separate offer documentation. Investments are speculative, high risk, and capital is at risk. Target returns are not guaranteed and past performance is not a reliable indicator of future performance. MAD Fund 1 is intended to be registered as an Early Stage Venture Capital Limited Partnership (ESVCLP); registration is currently conditional and the tax concessions described depend on unconditional registration and continuing compliance. Legislation may change. Prospective investors should obtain their own independent financial, legal and tax advice before making any investment decision. Nothing on this website should be relied on as a substitute for the Information Memorandum and Partnership Deed, available on request to eligible investors via the Investor Room.

© 2026 MAD Management Pty Ltd. All rights reserved.